Close Menu

NEW YORK – In a bid to improve the screening, and potentially treatment, of newborns with Duchenne muscular dystrophy (DMD), a coalition of stakeholders have embarked on a pilot study that if successful could beckon the routine screening of all babies in the US for the condition.

Additionally, data from the project could help in the development of new DMD drugs specifically for newborns.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.